Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

FOXO4-DRI cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established FOXO4-DRI cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • FOXO4-DRI combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established FOXO4-DRI cycle length?
No. We found no human studies that report a treatment duration for FOXO4-DRI.
What is the longest human study of FOXO4-DRI?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
FOXO4-DRI dosing reference Full research page

References

  1. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Cell. 2017
  2. FOXO4-DRI (CID 168431240): molecular formula C228H388N86O64, molecular weight 5358 PubChem. 2026
  3. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging Front Aging. 2026
  4. DailyMed drug name search returned no labels for FOXO4 (searched 22 October 2026) DailyMed. 2026
  5. ClinicalTrials.gov search for "FOXO4-DRI" returned 0 studies (searched 22 October 2026) ClinicalTrials.gov. 2026
  6. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  7. Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia Am J Respir Cell Mol Biol. 2024
  8. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging (Albany NY). 2020
  9. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway Front Bioeng Biotechnol. 2025
  10. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression Circulation. 2023
  11. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI Nat Commun. 2025
  12. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedebergs Arch Pharmacol. 2026
  13. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice Naunyn Schmiedebergs Arch Pharmacol. 2023
  14. FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting Antioxidants (Basel). 2026
  15. Targeting Multiple Homeostasis-Maintaining Systems by Ionophore Nigericin Is a Novel Approach for Senolysis Int J Mol Sci. 2022
  16. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026